Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacteria, a genus of probiotic bacteria commonly found in the human gut, has been investigated for its potential benefits in non-alcoholic fatty liver disease (NAFLD), a condition often associated with metabolic syndrome and gut dysbiosis. Several preclinical studies in animal models and a handful of human clinical trials suggest that supplementation with Bifidobacteria may help ameliorate NAFLD by modulating the gut microbiota, reducing systemic inflammation, and improving metabolic parameters. For example, a randomized controlled trial published in Hepatology Research (2014) reported that a probiotic mixture containing Bifidobacteria improved liver aminotransferase levels and hepatic steatosis in patients with NAFLD. Other studies have found that Bifidobacteria supplementation can decrease endotoxin levels and oxidative stress, both implicated in the pathogenesis of fatty liver disease. However, the evidence base is still limited, with relatively small sample sizes and heterogeneity in probiotic strains, dosages, and study designs. Systematic reviews and meta-analyses acknowledge potential benefits but emphasize the need for larger, high-quality trials to confirm these effects and clarify mechanisms. In summary, while there is emerging scientific support for the use of Bifidobacteria in fatty liver disease, the evidence is moderate and not yet definitive.

More about Bifidobacteria (unspecified)
More about Fatty Liver Disease

Other ingredients used for Fatty Liver Disease

Other health conditions supported by Bifidobacteria (unspecified)

Products containing Bifidobacteria (unspecified)